fevipiprant Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).   Wikipedia

Chemistry

  • SMILES: Cc1c(CC(=O)O)c2cccnc2n1Cc3ccc(cc3C(F)(F)F)S(=O)(=O)C
  • InChIKey: GFPPXZDRVCSVNR-UHFFFAOYSA-N
  • Mol. Mass: 426.42
  • ALogP: 3.44
  • ChEMBL Molecule:
    fevipiprant  
More Chemistry

Pharmacology

Alternative names

1-(4-methanesulfonylbenzyl)-2-methyl-1h-pyrrolo(2,3-b)pyridin-3-yl)acetic acid | fevipiprant | nvp-qaw039 | qaw039

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Asthma (Phase 4)

Dermatitis, Atopic (Phase 2)

Eosinophilia (Phase 2)

Liver Diseases (Phase 1)

Nasal Polyps (Phase 3)

Physiological Effects of Drugs (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Renal Insufficiency (Phase 1)

Rhinitis, Allergic (Phase 2)

Sinusitis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue